MedTrace Logo

Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab

NCT01077128 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2014-02-21

Study results available
· View outcomes & findings →

Summary

Primary objective

* To evaluate the quality of life of Adalimumab treated patients over a period of 12 months

Secondary objectives

* To evaluate the long-term efficacy of Adalimumab in patients with moderate to severe chronic plaque psoriasis as prescribed by the dermatologists in day-to-day clinical practice and in accordance with the terms of the European marketing authorization.
* To evaluate changes in patients quality of life according to treatment response over a 12-month period
* To observe and assess the long term use and safety of Adalimumab as prescribed by the dermatologist in a normal clinical setting and in accordance with the terms of the European marketing authorization.

Conditions

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Athina Katsavou, MD · AbbVie Pharmaceuticals S.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01077128 on ClinicalTrials.gov